Peptide Library

Human study PLS-00093

Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance.

Case-control study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance.primary · Pediatric diabetes · 2018-04-25 · PMID 29691953 · DOI

Design and participants

Design
Case-control study
Population
Obese children and adolescents (40, of whom 27 male) and non-obese controls (57, of whom 40 male), recruited in Hubei Province, China, in 2017
Conditions
Obesity, Insulin resistance
Setting
Recruitment in Hubei Province, China, 2017; clinical setting not further stated (China)
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety.

    Monitoring: Not applicable; no compound administered and no safety monitoring reported

    The authors concluded (paraphrased): Circulating MOTS-c was lower in obese male children and adolescents and correlated with markers of obesity and insulin resistance.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate endpoint: Measures endogenous MOTS-c levels only; no administration of MOTS-c, so no treatment effect can be inferred.
    • confounding: The observational case-control comparison gives no reported adjustment for confounders such as age, puberty or sex distribution.
    • inappropriate population: Children and adolescents with obesity, whereas the claim concerns adults with obesity, insulin resistance or T2DM.
    • small or imprecise: Small sample of 40 obese and 57 control participants; the male-only correlation analysis is smaller still.
    • abstract only: Only the abstract is available, so methods, assay details, funding and conflicts cannot be assessed.
    • other: No compound was administered; the study measures endogenous levels, so it cannot show any effect or safety of MOTS-c treatment.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • arms: PMID 29691953, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • author_conclusion: PMID 29691953, abstract (Conclusions, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 29691953, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 29691953, abstract (Methods and Results) · extracted by AI (automated, not verified by a person) · abstract only
    • outcomes: PMID 29691953, abstract (Methods, sentences 2-3) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 29691953, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 29691953, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • results: PMID 29691953, abstract (Results, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).